Clinical Trials Sponsored by SUGEN

Total 27 results

Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Wugen, Inc.

Not yet recruiting

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Squamous Cell Carcinoma of Head and Neck | Colorectal Cancer Metastatic
Wugen, Inc.

Recruiting

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

United States, Australia, Netherlands, France
Wugen, Inc.

Enrolling by invitation

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

T-cell Acute Lymphoblastic Leukemia | T-cell Lymphoblastic Lymphoma

United States, Australia
SUGEN

Completed

SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment

HIV Infections | Sarcoma, Kaposi

United States
Suven Life Sciences Limited

Recruiting

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Agitation | Alzheimer's Type Dementia

Croatia, United States, Poland, Serbia
Suven Life Sciences Limited

Completed

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Alzheimer's Disease

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects

Cognitive Disorder

United States
Suven Life Sciences Limited

Completed

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy (SUVN-G3031)

Narcolepsy

United States, Canada
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects (SUVN-911)

Depressive Disorder, Major

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

Cognitive Disorders

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Cognitive Disorders

United States
SUGEN

Completed

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
Suven Life Sciences Limited

Recruiting

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

Major Depressive Disorder

United States
Suven Life Sciences Limited

No longer available

Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy

Narcolepsy
Suven Life Sciences Limited

No longer available

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)

Dementia | Alzheimer Disease | Cognition Disorders
Suven Life Sciences Limited

Completed

Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects (SUVN-911)

Major Depressive Disorder

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Cognitive Disorders

United States
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG2918 For Advanced Malignant Tumors

Advanced Malignant Tumors

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.

Lymphoma | Hematological Malignancy

United States
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors (CSG-1827-101)

Advanced Solid Tumors

China
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors (CSG-1906-101)

Locally Advanced Unresectable or Metastatic Solid Tumors

China
Hangzhou Sumgen Biotech Co., Ltd.

Active, not recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Relapsed or Refractory Multiple Myeloma | Hematological Malignancy

China
Eugen Feist

Completed

An Animated Home-based Physical Exercise Program as a Treatment Option for Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Washington University School of Medicine
Wugen, Inc.

Withdrawn

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Myelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia
Washington University School of Medicine
Wugen, Inc.

Recruiting

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Acute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditions

United States

Clinical Trials Sponsored by SUGEN

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations